Navigation Links
DK Sinopharma, Inc. Reviews its Honors of the Year 2010

XI'AN, China, Jan. 6, 2011 /PRNewswire-Asia-FirstCall/ -- DK Sinopharma, Inc. (OTC Bulletin Board: DKSP) ("DK Sinopharma" or the "Company") reviewed the honors received in the year of 2010 to celebrate the achievements and successes over the past year.

In February 2010, the Company won an "Outstanding Contribution Award for the Economic Development" which was granted by the local government of Yangling Demonstration Zone.

In March 2010, the Company was assessed as "Excellent Pharmaceutical Company in Drug Quality Management in 2009" by Food and Drug Administration of Yangling Demonstration Zone.

On March 15, 2010, the Company was honored as "Shaanxi Credible Enterprise" by Shaanxi Provincial Commerce and Industry Bureau of Shaanxi Government.

In April 2010, one of the Company's Patented Products "Ganhai Stomach Recovery Capsule" was designated as Famous-Brand Product of Shaanxi by Brand Strategy Promotion Committee of Shaanxi Government. Also, the trademark of the Company "Yaowang Mountain" was re-designated as "Famous Trademark of Shaanxi Province" by Shaanxi Provincial Commerce and Industry Bureau of the Government.

Additionally in April 2010, the Company was elected as the Vice-Chairman Unit of Shaanxi Pharmaceutical Association while Professor Dongke Zhao, the CEO and president of DK Sinopharma, Inc. was elected as the Vice-Chairman of Shaanxi Pharmaceutical Association.

In September, the Company won an "Outstanding Contribution Award for the Western Development Program of Shaanxi Province", which was granted by Shaanxi Government, Shaanxi Commercial Association and General Chamber of Commerce of Shaanxi Province.

As of November 11, 2010, DK Sinopharma, Inc. has been designated as a Provincial Enterprise R&D Center by the Industry and Technology Information Department of Shaanxi Province and the Science and Technology Bureau of Shaanxi Province.

On December 8, 2010, DK Sinopharma, Inc. was honored at a grand awards ceremony for its designation as an "A-class taxpayer" in Shaanxi Provincial Tax Paying Credit Rating on September 30, 2010.

In July 2010, Professor Dongke Zhao, the founder and CEO of DKSP was awarded as "2010 National Excellent Member for Participation in State Politics" by National September Third Society and in December 2010 he was awarded as "Excellence Member for Participation in Provincial Politics" by Shaanxi Provincial September Third Society again.

"We were very pleased to review the great achievements the Company has made and the honors we won from the local, provincial and even the national governments in the year of 2010, which greatly reinforced the brand identity of our products in the market and eventually helped the increase of the sales revenue," said Professor Dongke Zhao, the founder and CEO of DK Sinopharma, Inc. "The products of the Company are well- recognized by the customers for the top quality and great curative effect in Shaanxi Province as well as across the whole country. We will take this great opportunity to keep on working with all our efforts on in-house R&D as well as promotion of our brand identity in the market. When we are looking back at the past results, we are confident to say that we will make greater achievement and win more in the new year as well as the following years."

About DK Sinopharma,Inc. DK Sinopharma, Inc. has its headquarters in Xi'an, Shaanxi Province, China. The Company identifies, discovers, develops, manufactures and distributes both prescription and over-the counter, including both conventional and Traditional Chinese Medicines, pharmaceutical products for the treatment of some of the most common ailments and diseases. Through the Company's operating entity, Yangling Dongke Maidisen Pharmaceutical Co. Ltd., the Company currently manufactures herbal extracts and 38 pharmaceutical products in the form of capsules, tablets, granules, semisolid ointment, powder, ointment, and paste ointment. The Company focuses on providing remedies to a variety of ailments relating to respiratory, digestive, cardio-cerebral vascular, antineoplastic, bone diseases-modifying antirheumatic, gynecological, and refill nutrition systems, among others. DK Sinopharma, Inc.'s manufacturing facilities are based in the City of Yangling in Shaanxi Province. For more information see our website at

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the company's ability to raise additional capital to finance the company's activities; the effectiveness, profitability, and the marketability of its products; legal and regulatory risks associated with the share exchange; the future trading of the common stock of the company; the ability of the company to operate as a public company; the period of time for which its current liquidity will enable the company to fund its operations; the company's ability to protect its proprietary information; general economic and business conditions; the volatility of the company's operating results and financial condition; the company's ability to attract or retain qualified senior management personnel and research and development staff; and other risks detailed in the company's filings with the Securities and Exchange Commission and available on its website at These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the companies and the industry. The company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the company believes that the expectations expressed in these forward looking statements are reasonable, they cannot assure you that their expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results. DK Sinopharma, Inc.Mr. Dongke Zhao, President and Chief Executive Officer
Ms. Yanhong Ren, Chief Financial Officer
Ms. Emily Zhang, Vice President of Corporate Communications86-29-8224-7500-8612

SOURCE DK Sinopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DK Sinopharma, Inc. is Honored as A-class Taxpayer for the Third Time
2. Obesity Organizations Call for a Full and Fair Hearing When the FDA Reviews New Treatments for Obesity
3. Misonix Previews New OsteoSculpt® Ultrasonic Bone Scalpel
4. Pharmaxis Previews New Bronchial Challenge Test at the Annual Meeting of the American College of Allergy, Asthma and Immunology
5. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
6. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
7. GSK Regulatory Update on Avandia Following EMA and FDA Reviews
8. Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance
9. Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases
10. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
11. Charlotte Business Journal Honors Prodigy Diabetes Care, LLC With Fast 50 Award
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
Breaking Medicine Technology:
(Date:11/26/2015)... Bangalore, Karnataka (PRWEB) , ... ... ... an innovative online platform for mental health and wellness consultation, has collaborated ... self-empowerment, to holistically address their reader’s queries on topics on mental and ...
(Date:11/25/2015)... Indianapolis, IN (PRWEB) , ... November 25, 2015 ... ... clean water accessible for all, Water For Empowerment ™ attracts volunteers together ... on clean water by empowering women as key stakeholders in the process. The ...
(Date:11/25/2015)... Neb. (PRWEB) , ... November 25, 2015 , ... ... staffing companies, has been recognized once again for its stellar workplace culture with ... to Work.” , Medical Solutions’ Cincinnati office was named a finalist ...
(Date:11/25/2015)... ... , ... Ministers, senior government and UN agencies, representatives from ... Excellence, and public R&D institutions, civil societies and other partners gathered today at ... Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day meeting ...
(Date:11/25/2015)... Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... da Vinci surgical robot is being more and more widely heralded as a breakthrough ... assisted da Vinci method has over traditional laparoscopic surgery is that it can greatly ...
Breaking Medicine News(10 mins):